ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

2:00PM-3:30PM: Abstract Number: 0754

Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0790

Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0760

Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

2:00PM-3:30PM: Abstract Number: 0752

Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0787

Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0737

Unraveling Pathophysiology and Hematopoiesis of VEXAS Syndrome by Multi-omics Analysis and Targeted Gene Editing

Abstracts: Genetics, Genomics & Proteomics

2:00PM-3:30PM: Abstract Number: 0768

Using Participatory Design-Thinking Process to Create a More Applicant-Centered Rheumatology Fellowship Interview Experience

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0756

Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative

Abstracts: Measures & Measurement of Healthcare Quality

2:00PM-3:30PM: Abstract Number: 0788

Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0731

ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:30PM: Abstract Number: 0798

A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages

Abstracts: RA – Animal Models

4:00PM-5:30PM: Abstract Number: 0837

A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis

Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action

4:00PM-5:30PM: Abstract Number: 0825

A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0835

Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial

Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action

4:00PM-5:30PM: Abstract Number: 0816

Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].